Eikon Therapeutics IPO Brings in $381M for Oncology Pipeline

Eikon Therapeutics priced an upsized initial public offering (IPO) of 21,177,600 shares of common stock at $18 per share. 

It raised about $381 million in gross proceeds before underwriting discounts and offering expenses. The company began trading on the Nasdaq Global Select Market on February 5 under the ticker EIKN. The offering was expected to close on February 6.

According to Reuters, the IPO valued Eikon at roughly $860 million at its Nasdaq debut.

Eikon Therapeutics is a California-based biotech developing cancer drugs targeting immune signaling, DNA repair pathways and androgen receptor biology.

Its pipeline includes three licensed programs: the TLR7/8 agonist EIK1001 and the selective PARP1 inhibitors EIK1003 and EIK1004.

The company also develops drug candidates using its single molecule tracking platform, which tracks individual protein molecules in living cells to study how potential drugs interact with disease targets.

The most advanced candidate is EIK1001, a toll-like receptor 7 and 8 (TLR7/8) dual agonist designed to stimulate anti-tumor immune responses. 

TLR7/8 agonists activate immune pathways that help the body recognize and attack cancer cells. Because they stimulate immune responses involved in tumor recognition, researchers are studying them as partners for therapies such as checkpoint inhibitors, chemotherapy and cancer vaccines.

Eikon is evaluating EIK1001 in a global Phase II/III trial with Merck’s Keytruda (pembrolizumab) for advanced melanoma. The drug is also being tested in a US Phase II trial in non-small cell lung cancer (NSCLC) combining pembrolizumab with histology-appropriate chemotherapy.

EIK1001 has been studied in more than 400 patients, according to the company prospectus. In the ongoing Phase II NSCLC study, Eikon reported no dose-limiting toxicities at the run-in dose and a 60% tumor response rate among 53 evaluable patients. These findings will require confirmation in larger registrational trials. Eikon expects an interim melanoma trial analysis in the second half of 2026 and plans to initiate a global Phase II/III registrational study in metastatic NSCLC in the same timeframe.

The pipeline also includes two selective PARP1 inhibitors, EIK1003 and EIK1004, designed to inhibit PARP1 while sparing PARP2. Eikon believes this approach may reduce the hematologic toxicity associated with earlier PARP inhibitors.

EIK1003 is being studied in a Phase I/II trial for ovarian, breast, prostate and pancreatic cancers. In the monotherapy dose-escalation stage, Eikon reported a 14% tumor response rate among 49 evaluable patients. The drug is also being assessed in combination regimens with abiraterone and prednisone for prostate cancer and with paclitaxel for platinum-resistant ovarian and breast cancers. Additional data from these studies are expected in the second half of 2026.

EIK1004 is a selective PARP1 inhibitor designed to reach the central nervous system. It is also in Phase I/II testing in ovarian, breast, prostate and pancreatic cancers, including tumors involving brain metastases or primary brain malignancies. Dose escalation was ongoing as of late 2025 and is expected to conclude in the second half of 2026 if a maximum tolerated dose is identified.

In addition to these external programs, Eikon is developing internal candidates. One of these, EIK1005, targets WRN helicase and is under study for tumors with microsatellite instability-high status. The company has launched a Phase I/II trial in advanced solid tumors and plans to evaluate the drug as both monotherapy and in combination with pembrolizumab. Eikon expects to dose the first patient in early 2026.

Another internal candidate, EIK1006, is being developed as an androgen receptor antagonist for prostate cancer. The program remains in IND-enabling studies, and the company plans to submit an IND application in the first quarter of 2027.

Eikon’s research pipeline also includes an androgen receptor variant 7 program and ongoing discovery efforts in oncology and neurologic diseases. The IPO proceeds will support ongoing clinical studies and further development of its research programs.

Other companies are also exploring the TLR7/8 mechanism in oncology. In February 2026, SURGE Therapeutics announced it had completed dosing in a Phase I study of SRG-514, an investigational therapy for breast cancer patients undergoing tumor-removal surgery. The company said the treatment was generally well tolerated and is preparing a registrational trial following discussions with the FDA. SURGE is also developing intraoperative immunotherapy programs using the TLR7/8 agonist resiquimod, including STM-416 and STM-416p for bladder and prostate cancer.

If you want your company to be featured on Xtalks.com, please email [email protected].